Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

NCT05591755 | Completed Phase 3 Results FDA Drug

• 1 other identifier: 910
• Study Type: interventional
• Target: 229
• Locations: 1 country
• Sites: 6

Brief Summary

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Conditions

Seasonal Allergic Conjunctivitis

Outcome Measures

Primary Outcomes (2)

• Ocular Itching Symptom Score

  Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.

  Assessed up to 480 minutes post-instillation of assigned IP

• Ocular Redness Measured by Ocular Itching Scale

  Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

  Assessed up to 480 minutes post-instillation of assigned IP

Secondary Outcomes (3)

• Tearing Measured by Watery Eyes Scale

  up to 480 minutes post-instillation of assigned IP

• Lid Swelling Measured by Eyelid Swelling Scale

  up to 480 minutes post-instillation of assigned IP

• Chemosis Evaluated

  up to 480 minutes post-instillation of assigned IP

Study Arms (4)

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

EXPERIMENTAL

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Ketotifen fumarate ophthalmic solution 0.035%

EXPERIMENTAL

Ketotifen fumarate ophthalmic solution 0.035%

Drug: Ketotifen fumarate ophthalmic solution 0.035%

Brimonidine tartrate ophthalmic solution 0.025%

EXPERIMENTAL

Brimonidine tartrate ophthalmic solution 0.025%

Drug: Brimonidine tartrate ophthalmic solution 0.025%

Vehicle ophthalmic solution

EXPERIMENTAL

Vehicle ophthalmic solution

Drug: Experimental: Vehicle ophthalmic solution

Interventions

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution DRUG

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Ketotifen fumarate ophthalmic solution 0.035% DRUG

Ketotifen fumarate ophthalmic solution 0.035%

Ketotifen fumarate ophthalmic solution 0.035%

Brimonidine tartrate ophthalmic solution 0.025% DRUG

Brimonidine tartrate ophthalmic solution 0.025%

Brimonidine tartrate ophthalmic solution 0.025%

Experimental: Vehicle ophthalmic solution DRUG

Experimental: Vehicle ophthalmic solution

Vehicle ophthalmic solution

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must:
• be at least 18 years of age of either sex and any race;
• provide written informed consent and sign the Health Information Portability and Accountability Act (HIPAA) form;
• be willing and able to follow all instructions and attend all study visits;
• provide proof of COVID-19 vaccination
• be able and willing to discontinue wearing contact lenses for at least 72 hours prior to Visit 2 and for the duration of the visit;
• have seasonal allergic conjunctivitis to ragweed or timothy grass documented by a self-reported history of ocular allergic symptoms for the last 2 consecutive years during the ragweed or timothy grass seasons and a positive skin test reaction to ragweed or timothy grass pollen as confirmed by the allergic skin test given at or within 24 months of the subject's Visit 1;
• (If female and of childbearing potential) agree to have urine pregnancy testing performed at visit 2, (must be negative); must not be lactating; and must agree to use at least 1 medically acceptable form of birth control throughout the study duration, for at least 14 days prior to and 1 month after receiving investigational drug. Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject), spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of male partner at least 3 months prior to receiving investigational drug (Visit 2). Note: Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
• (If male and with female partner of childbearing potential) must use at least 1 medically acceptable form of birth control· Note: Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject) or vasectomy at least 3 months prior to receiving investigational drug (Visit 2). Without a vasectomy, must use condoms with spermicidal foam/gel/film/cream/suppository throughout the study duration, for at least 14 days prior to and 1 month after investigational drug (Visit 2).
• have a calculated visual acuity (VA) of 0.7 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1;
• have a positive Allergen BioCube challenge response to pollen exposure at the 90 minute time point of ABC exposure at Visit 2, defined as bilateral score of \>2 in ocular itching and ocular redness.

You may not qualify if:

• Subjects may not:
• have known contraindications or sensitivities to the use of any of the investigational product medication or components;
• have a history of mild persistent, moderate or severe asthma within the preceding 5 years according to the National Heart, Blood, and Lung Institute classification (with the exception of exercise induced asthma).
• Note: Subjects with fall induced asthma that is either mild persistent (defined as \>1 per week, but \<1 per day), moderate persistent, or severe persistent will be excluded.
• have an upper respiratory tract or sinus infection within the previous 2 weeks of Visit 1;
• have a history of anaphylaxis or poor tolerability of previously administered allergen;
• have a compromised lung function at Visit 1 (defined as a peak expiratory flow rate \[PEFR\] that is below 80% of the predicted average PEFR, as calculated by gender, age, and measured height from the Mini-Wright instruction's table: Normal Adult Predicted Average Peak Expiratory Flow).
• have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg) at Visit 1;
• have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, or a diagnosis of dry eye);
• have had ocular surgical intervention within three months prior to Visit 1, or during the trial or a history of refractive surgery six months prior to Visit 1, or have systemic surgery planned during the clinical trial or within 30 days after;

Sponsors & Collaborators

• Bausch & Lomb Incorporated: lead

Study Sites (6)

104 Butchertown Clinical Trials

Louisville, Kentucky, 40206, United States

Location

101 Andover Eye Associates

Andover, Massachusetts, 01810, United States

Location

105 - Advancing Vision Research

Goodlettsville, Tennessee, 37072, United States

Location

102 Total Eye Care, PA

Memphis, Tennessee, 38119, United States

Location

108 Emerson Clinical Research Institute Inc.

Falls Church, Virginia, 22046, United States

Location

107 Virginia Eye Institute

Richmond, Virginia, 23230, United States

Location

MeSH Terms

Interventions

Brimonidine Tartrate; Ketotifen; Ophthalmic Solutions

Intervention Hierarchy (Ancestors)

Quinoxalines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Thiophenes; Sulfur Compounds; Organic Chemicals; Piperidines; Heterocyclic Compounds, 1-Ring; Pharmaceutical Solutions; Solutions; Pharmaceutical Preparations; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses; Specialty Uses of Chemicals

Results Point of Contact

• Title: Daniel Donatello
• Organization: Bausch & Lomb

Daniel.Donatello@bausch.com

5853385306

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2022
• First Posted: October 24, 2022
• Study Start: November 18, 2022
• Primary Completion: August 9, 2023
• Study Completion: August 9, 2023
• Last Updated: July 1, 2025
• Results First Posted: July 1, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (6)